Key Takeaways:
-
Market Growth: The bispecific market is expected to quadruple by 2030, putting pressure on developers to move candidates to the clinic faster
-
Stability and Ratios: Semi-targeted integration solves the problem of incorrect chain pairing and genetic instability in CHO cells
-
10x Productivity: Transposase-driven pools can reach titers up to 10 times higher than those produced by random integration
-
Screening Power: Automated high-throughput systems can screen 6,400+ clones simultaneously to accelerate timelines
The bispecific antibody market is on a fast trajectory. It is projected to grow from roughly $10 billion in 2025 to $41 billion by 20301. While this pipeline growth is a win for clinical science and patient care, it uncovers a major manufacturing bottleneck. Traditional cell line development (CLD) processes for bispecifics are struggling to keep pace with the structural complexity of these molecules. This gap between therapeutic potential and production reality is the central problem for the next generation of biopharmaceuticals.
Why do standard random integration methods fail for complex proteins?
Standard random integration methods often fail when applied to multispecific antibodies. These molecules require precise assembly of different protein chains, but random gene insertion into CHO cells is unpredictable. This often results in genetic instability and incorrect chain ratios, leading to low titers or high levels of product impurities. Scientists must then manage the burden of 30, 60, or 90-generation stability studies to ensure the cell line remains productive over time. These studies take months and increase the risk of program delays. Because the genes are placed in unknown locations in the genome, the resulting cell pools often lack the consistency needed for reliable scale-up. This unpredictability makes it difficult for CMC leads to meet aggressive clinical timelines or guarantee a stable manufacturing process for the life of the drug.
How does transposase technology solve protein expression challenges?
Semi-targeted integration via transposase platforms provides a more reliable alternative. One of the industry’s most effective transposase systems currently is the ATUM Leap-In Transposase® platform, which targets open, transcriptionally active chromatin for insertion. This ensures that the gene cassettes for all chains integrate together in the desired ratios. Data indicates that semi-targeted integration in CHO cells using this method can achieve up to a 10-fold improvement in titers compared to random integration. This platform also creates high consistency between stable pools and derivative clones, which allows teams to make data-driven decisions earlier in the process.
To further accelerate selection, utilizing automated, high-throughput screening technology, such as the Beacon® Optofluidic system is also something AGC Biologics has found to be extremely beneficial when developing cell lines. These systems can analyze more than 6,400 clones simultaneously, which is significantly more than the sub-1,000 clone capacity of traditional manual approaches. By combining targeted integration with massive screening capacity, developers can identify the most stable and productive clones in less time. This precision reduces the need for extensive stability studies and ensures clinical material is ready for manufacturing faster.
Technological innovation is playing a transformative role in advancing CGT manufacturing toward greater scalability, consistency, and cost-efficiency
“While each molecule is different, the transposase capabilities allow AGC experts to quickly assess metrics like product quality, scalability, and purification methods or other elements of process development… In addition to accelerating the customer’s timeline, efficient and transparent screening equips customers with comprehensive data to make well-informed decisions about how best to proceed with a molecule.”
- Kayla Bean, Sr. Manager, Technology & Innovation, “Solving Atypical Protein Expression with Transposase”
Why is early CDMO partnership critical for bispecific development?
Starting a partnership with a CDMO for bispecific antibody development early in the process can prevent technical overruns. Complex molecules require a flexible platform that can be adapted to their unique structural requirements. A partner that offers transparent data sharing and proactive molecule-specific adaptation can identify potential manufacturing hurdles during the identification stage. This early collaboration reduces the risk of technical failures during scale-up. By selecting a CDMO with a global network and a history of commercial success, sponsors ensure their program can transition smoothly from the clinic to commercial production. This partnership de-risks the development path and provides the technical expertise needed to navigate complex regulatory landscapes.
_____________________________
Download our white paper, “Solving Atypical Protein Expression with Transposase,” for a deeper look into optimizing your cell line development strategy.
You can learn more about this topic in our recent webinar “Cracking the Code on Complex Proteins: Process Innovation and Scalable Production”.
EXPLORE OUR MAMMALIAN SERVICES
Resources:
1. Research and Markets. Bispecific Antibody Market - Global Forecast to 2030. https://www.researchandmarkets.com/report/bispecific-antibodies
